The 2nd Annual European RWE & Market Access Summit 2026 is the pharmaceutical industry’s definitive Implementation War Room, designed to navigate the high-stakes transition into the New European HTA Era. As Joint Clinical Assessments (JCA) become mandatory for oncology and ATMPs, the mission of this summit is to provide Market Access, HEOR, and RWE leaders with a technical roadmap for the critical 100-day submission window.

This specialized 2026 edition moves beyond theory, delivering actionable insights into PICO strategy (Population, Intervention, Comparator, and Outcome), bias mitigation, and the operationalization of DARWIN EU 2.0 for regulatory-grade evidence generation. By attending, cross-functional teams will master national HTA readiness, aligning global evidence planning with EMA technical requirements and multi-state payer priorities. From Evidence-to-Access frameworks to solving PICO anxiety, this summit is the essential briefing for ensuring your 2026–2028 pipeline achieves successful reimbursement and long-term market sustainability across Europe.